PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety

Ann Hematol. 2018 Jan;97(1):193-196. doi: 10.1007/s00277-017-3127-2. Epub 2017 Sep 6.

Authors

Thomas S Y Chan¹, Jamilla Li¹, Florence Loong², Pek-Lan Khong³, Eric Tse¹, Yok-Lam Kwong⁴

Affiliations

¹ Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
² Department of Pathology, Queen Mary Hospital, Hong Kong, China.
³ Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China.
⁴ Department of Medicine, Professorial Block, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. ylkwong@hkucc.hku.hk.

PMID: 28879531
DOI: 10.1007/s00277-017-3127-2

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged, 80 and over
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Asparaginase / administration & dosage
Drug Evaluation
Drug Resistance, Neoplasm
Fatal Outcome
Female
Humans
Lymphoma, Extranodal NK-T-Cell / drug therapy
Male
Middle Aged
Molecular Targeted Therapy*
Nivolumab
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Programmed Cell Death 1 Receptor / immunology
Recurrence
Salvage Therapy

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
Asparaginase